Q3 EPS Estimates for Gossamer Bio Increased by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – Stock analysts at HC Wainwright upped their Q3 2026 EPS estimates for Gossamer Bio in a research note issued on Monday, September 21st. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($3.81) per share for the quarter, up from their prior estimate of ($4.00). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($32.80) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2026 earnings at ($1.95) EPS, FY2026 earnings at ($21.00) EPS, Q1 2027 earnings at ($1.82) EPS, Q2 2027 earnings at ($1.85) EPS, Q3 2027 earnings at ($1.08) EPS, Q4 2027 earnings at ($1.10) EPS, FY2027 earnings at ($5.64) EPS, FY2028 earnings at ($4.16) EPS, FY2029 earnings at ($1.48) EPS and FY2030 earnings at $2.60 EPS.

A number of other equities research analysts have also weighed in on the company. Weiss Ratings upgraded Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research report on Tuesday, July 28th. Finally, Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $256.00.

Gossamer Bio Stock Performance

Shares of GOSS opened at $11.69 on Wednesday. Gossamer Bio has a 52 week low of $9.10 and a 52 week high of $309.60. The stock has a market capitalization of $34.30 million, a price-to-earnings ratio of -0.21 and a beta of 2.00. The stock has a fifty day moving average of $13.12 and a 200-day moving average of $19.95.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GOSS. Hsbc Holdings PLC raised its holdings in Gossamer Bio by 1,289.4% during the 2nd quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after purchasing an additional 1,469,175 shares during the last quarter. Corient Private Wealth LP acquired a new position in Gossamer Bio in the second quarter valued at approximately $926,000. Kalehua Capital Management LLC bought a new stake in shares of Gossamer Bio in the 1st quarter valued at $3,363,000. Hhlr Advisors LTD. acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at about $819,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Gossamer Bio during the second quarter worth approximately $2,467,000. 81.23% of the stock is owned by institutional investors.

Gossamer Bio News Summary

Here are the key news stories impacting Gossamer Bio this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for several periods, including Q3 2026, Q2–Q4 2027, FY2027, FY2028 and FY2029. The FY2027 loss estimate improved to $5.64 per share from $7.20, while the FY2029 loss estimate narrowed to $1.48 from $2.40, suggesting analysts see improving profitability over time.
• Positive Sentiment: The analyst’s long-term model still projects Gossamer Bio reaching positive earnings by FY2030, at an estimated $2.60 per share, despite a reduction from the previous $4.00 forecast.
• Neutral Sentiment: Gossamer Bio remains a highly speculative biotechnology stock, with a very small market capitalization and significant share-price volatility. The company’s current full-year consensus estimate calls for a $32.80-per-share loss, underscoring the importance of future clinical and business developments. Gossamer Bio stock gains in the latest quote
• Negative Sentiment: HC Wainwright lowered its estimates for FY2026, Q4 2026 and Q1 2027, indicating somewhat weaker near-term earnings expectations. It also cut the FY2030 forecast from $4.00 to $2.60 per share, tempering the longer-term upside case.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.